Invea Therapeutics, Inc.
Invea Therapeutics is a biotechnology company dedicated to developing safe and effective oral small molecule therapeutics for immune-mediated inflammatory diseases (IMIDs). Using artificial intelligence (AI) and machine learning (ML), they aim to decode the mechanisms driving inflammation and develop transformational medicines. Their pipeline includes programs like INVA8001, a chymase inhibitor targeting mast cell-driven inflammation, and INVA8003, a pan-inflammasome inhibitor targeting ASC protein, with the goal to improve treatment options for conditions such as atopic dermatitis, chronic urticaria, and other IMIDs.
Industries
Nr. of Employees
small (1-50)
Invea Therapeutics, Inc.
Guilford, Connecticut, United States, North America
Products
Clinical-stage oral chymase inhibitor (mast cell-targeted small molecule)
An orally administered small molecule designed to selectively inhibit chymase to modulate mast cell-driven inflammation; advanced into early clinical development for mast cell-related IMIDs (e.g., chronic urticaria, atopic dermatitis) with reported preclinical evidence and planned Phase 1/2 studies.
Preclinical oral pan-inflammasome (ASC) inhibitor
A novel small molecule intended to inhibit ASC-mediated inflammasome assembly with broad anti-inflammatory potential across inflammasome-driven IMIDs; currently in preclinical development.
Colon-targeted oral 5-HT3 receptor inhibitor formulation (discovery-stage)
An orally delivered, colon-targeted formulation of a small molecule 5-HT3 receptor inhibitor developed for treatment of moderate to severe ulcerative colitis (IBD); described as a formulation / delivery-stage program in the discovery pipeline.
Discovery pipeline of AI-prioritized small molecule candidates
Ongoing discovery and design of additional small molecule product candidates using an AI/ML platform to prioritize targets and leads, with options to in-license or design in-house.
Clinical-stage oral chymase inhibitor (mast cell-targeted small molecule)
An orally administered small molecule designed to selectively inhibit chymase to modulate mast cell-driven inflammation; advanced into early clinical development for mast cell-related IMIDs (e.g., chronic urticaria, atopic dermatitis) with reported preclinical evidence and planned Phase 1/2 studies.
Preclinical oral pan-inflammasome (ASC) inhibitor
A novel small molecule intended to inhibit ASC-mediated inflammasome assembly with broad anti-inflammatory potential across inflammasome-driven IMIDs; currently in preclinical development.
Colon-targeted oral 5-HT3 receptor inhibitor formulation (discovery-stage)
An orally delivered, colon-targeted formulation of a small molecule 5-HT3 receptor inhibitor developed for treatment of moderate to severe ulcerative colitis (IBD); described as a formulation / delivery-stage program in the discovery pipeline.
Discovery pipeline of AI-prioritized small molecule candidates
Ongoing discovery and design of additional small molecule product candidates using an AI/ML platform to prioritize targets and leads, with options to in-license or design in-house.
Services
AI/ML-powered target and drug discovery services
Application of an AI/ML platform and data-integration workflows to identify and prioritize therapeutic targets, generate testable hypotheses, and support lead discovery for IMIDs.
Partnership and licensing engagement
Strategic collaborations including in-licensing, out-licensing/co-development, and other partnership models to advance programs and expand geographic/commercial rights.
AI/ML-powered target and drug discovery services
Application of an AI/ML platform and data-integration workflows to identify and prioritize therapeutic targets, generate testable hypotheses, and support lead discovery for IMIDs.
Partnership and licensing engagement
Strategic collaborations including in-licensing, out-licensing/co-development, and other partnership models to advance programs and expand geographic/commercial rights.
Expertise Areas
- AI-driven drug discovery and target prioritization
- Small molecule therapeutics for immune-mediated inflammatory diseases
- Gut-brain and gut-liver axis biology
- Inflammasome and mast cell biology
Key Technologies
- Artificial intelligence / machine learning for biomedical data integration
- Knowledge graph and target association networks
- Network biology and systems pharmacology
- Small molecule medicinal chemistry